Evaluation of Trimethylamine N-oxide (TMAO) Levels in Periodontal Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-08

Study Completion Date

2024-09-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Salivary and serum levels of TMAO and TNF-α can distinguish between individuals with periodontitis and periodontally healthy individuals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trimethylamine N-oxide (TMAO) Levels in Periodontal Disease

NCT06580431

Periodontitis Smoking Inflammatory Response

COMPLETED NA

Assessment of Salivary Biomarker Levels in Individuals With Various Periodontal Diseases

NCT07025291

Periodontal Diseases

RECRUITING NA

EVALUATION OF SALIVARY BİOMARKER LEVELS IN SMOKING AND NON-SMOKER INDIVIDUALS WITH DIFFERENT PERIODONTAL DISEASES

NCT06971770

Periodontal Diseases

COMPLETED NA

Evaluation of Free Aminoacids in Saliva as A Diagnostic Biomarker of Periodontal Disease

NCT04642716

Periodontitis Diagnoses Disease

COMPLETED NA

Evaluation of Oxidative Stress and Methylated Arginine Levels in Individuals With Periodontitis

NCT06973148

Periodontitis Oxidative Stress

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Trimethylamine N-oxide (TMAO), a gut flora-derived metabolite from dietary choline, has emerged as an indicator of atherosclerosis. Circulatory TMAO has been implicated in cardiovascular risks by altering enterohepatic cholesterol and bile acid metabolism, increasing macrophage scavenger receptor expression, and activating nuclear factor kappa B (NF-κB) via pro-inflammatory genes such as interleukin-1 (IL-1). The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α), which plays a crucial role in immune responses and inflammation, has been demonstrated as a crucial participant also during the development of periodontal diseases. The aim of this study is to evaluate difference in salivary and serum levels of TMAO and TNF-α between individuals with periodontitis and periodontally healthy individuals.

The study includes two groups: systemically and periodontally healthy control subjects (n= 24), and patients with periodontitis (n=24). Periodontal parameters were recorded. TMAO levels in saliva and serum were determined by liquid chromatography-mass spectrometry (LC-MS/MS), and TNF-α levels were determined by ELISA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontitis Inflammation Trimethylamine N-oxide (TMAO) TNF-alfa

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.